Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Goto Application

1. WO2020068764 - ANTICORPS ANTI-CD30 ET PROCÉDÉS D'UTILISATION

Numéro de publication WO/2020/068764
Date de publication 02.04.2020
N° de la demande internationale PCT/US2019/052618
Date du dépôt international 24.09.2019
CIB
C07K 16/28 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
16Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
18contre du matériel provenant d'animaux ou d'humains
28contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
CPC
A61K 47/6849
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6849the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
C07K 16/2878
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2878against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C07K 16/462
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
461Igs containing Ig-regions, -domains or -residues form different species
462Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/41
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
40characterized by post-translational modification
41Glycosylation, sialylation, or fucosylation
C07K 2317/51
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
51Complete heavy chain or Fd fragment, i.e. VH + CH1
Déposants
  • THE MEDICAL COLLEGE OF WISCONSIN, INC. [US]/[US]
Inventeurs
  • MEDIN, Jeffrey A.
  • FABER, Mary L.
  • TATE, Everett R.
  • OLDHAM, Robyn A.A.
Mandataires
  • BABEL, Angeline R.
Données relatives à la priorité
62/735,50824.09.2018US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) ANTI-CD30 ANTIBODIES AND METHODS OF USE
(FR) ANTICORPS ANTI-CD30 ET PROCÉDÉS D'UTILISATION
Abrégé
(EN)
The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.
(FR)
La présente invention concerne de nouveaux anticorps et des fragments de liaison à l'antigène de ceux-ci qui se lient à CD30 humain. L'invention concerne également des anticorps variables à chaîne unique, des récepteurs antigéniques chimériques et leurs utilisations. L'invention concerne en outre des méthodes de traitement du cancer.
Dernières données bibliographiques dont dispose le Bureau international